Biogen CEO Viehbacher outlines a path, including immunology, rare diseases
While Biogen's new CEO says he isn't planning any "radical left turns," he does see some ways the company could tap into new markets, including immunology and rare diseases. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 10, 2023 Category: Biotechnology Authors: Rowan Walrath Source Type: news
At #JPM23, another rare disease buyout as Ipsen acquires Albireo for $952M
Before most JPMers arose Monday morning, Ipsen announced that it is buying rare disease biotech Albireo Pharma. That’s the second deal disclosed Monday morning, along with AstraZeneca grabbing cardiovascular upstart CinCor Pharma. With the Chiesi-Amryt rare disease deal…#cholestatic #roncooper #medicines #albireo #arena #epizyme #vielabio #albo #expanded #into2024 (Source: Reuters: Health)
Source: Reuters: Health - January 10, 2023 Category: Consumer Health News Source Type: news
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
None Ipsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in cash for an initial estimated aggregate consideration of $952 million plus one contingent value right (CVR) per share. • None Each CVR will entitle its holder to deferred cash payments of $10.00…#biliary #fda #albireopharmainc #bylvay #ipsen #nonepriceaction #albireo (Source: Reuters: Health)
Source: Reuters: Health - January 9, 2023 Category: Consumer Health News Source Type: news
Italy ’s Chiesi Farmaceutici to buy Amryt Pharma in a $1.48-billion deal
Italy’s Chiesi Farmaceutici said on Sunday it will acquire Ireland-based drugmaker Amryt Pharma Plc, which has products and drugs in development for treating rare diseases, in a deal valued at $1.48 billion. The total value of the all-cash deal represents a 107 per cent premium over Dublin,…#marcovecchia #ireland #chiesifarmaceutici #myalept #amryt #filsuvez #dublin #amrytpharmaplc #chiesigroup (Source: Reuters: Health)
Source: Reuters: Health - January 8, 2023 Category: Consumer Health News Source Type: news
Pfizer Explores Options for Some Rare Disease, Cancer Drugs Pfizer Explores Options for Some Rare Disease, Cancer Drugs
Pfizer is exploring options for some early stage treatments for rare diseases and cancer in a bid to focus on ' high-impact ' medicines and vaccines, the company said on Thursday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 6, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Why Pfizer Is Pulling Back on Research Into Rare Disease, Gene Therapy
Pfizer is planning to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies, the company told employees on Thursday afternoon. The company said it would “externalize” most of its early-stage rare disease programs in…#northcarolina #durham (Source: Reuters: Health)
Source: Reuters: Health - January 6, 2023 Category: Consumer Health News Source Type: news
Pfizer could sell some assets, convert others into new companies amid broader refocus
Drug maker Pfizer Inc. could part with or distance itself from some of its research programs as it rethinks its approach to early development research in rare diseases and cancer treatments, the company said Thursday. The move by Pfizer PFE, would mark a considerable shift for a company trying to…#pfizerinc #bofa #marketwatch #pfizerpfe #pfizer #durham #barrons #rsv #boulder #colo (Source: Reuters: Health)
Source: Reuters: Health - January 6, 2023 Category: Consumer Health News Source Type: news
Palvella Therapeutics raises $9.7M to advance drug candidate targeting multiple rare diseases
The company's lead experimental drug is being tested as a treatment for three different rare diseases, with more on the horizon. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 6, 2023 Category: Health Management Authors: John George Source Type: news
Incurable liver disease may prove curable
Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the liver, could be reversed with a single drug. The study, published in the Proceedings of the National Academy of Sciences, has the potential to transform treatment for this rare disease and may also have implications for more common diseases. (Source: World Pharma News)
Source: World Pharma News - January 5, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Jazz Musician With Slowly Expanding Neck Mass Causing Dysphagia
(MedPage Today) -- Alcoholism, liver dysfunction highly linked with rare disease of unknown etiology (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 4, 2023 Category: Hematology Source Type: news
Kenya: Alarm Raised Over Rare Disease Affecting Fishermen Within Lake Victoria
[Capital FM] Kisumu -- An alarm has been raised of a rare disease attacking fishermen in two beaches within Lake Victoria in Nyando Sub County. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 29, 2022 Category: African Health Source Type: news
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 27, 2022 Category: Drugs & Pharmacology Source Type: news
Families Push Research Forward in Rare Diseases
(MedPage Today) -- This story was supported by a grant from the National Press Foundation in partnership with Fondation de France. For the main story on how mRNA is being investigated for its potential in rare diseases, click here.
Kathy Stagni... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - December 26, 2022 Category: Pediatrics Source Type: news
Lab Notes: Chimeron Bio names new CEO; Amicus Therapeutics gets positive opinion for rare disease therapy
This week's Philadelphia-area life sciences industry news includes a biotechnology firm naming a new CEO, positive study results on an experimental cancer therapy for another, progress on a potential treatment for a rare disorder for a third, and more.
Here is the roundup:
The Philadelphia biotechnology company developing self-amplifying RNA vaccines and therapeutics has named Kevin Heyeck as its new CEO.
He succeeds former chief executive Jolly Mazumdar, who departed the post earlier this month … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 23, 2022 Category: American Health Authors: John George Source Type: news
FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), FDA Approved for Treatment of Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available at Biologics by McKesson
CARY, N.C., Dec. 22, 2022 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Aadi Bioscience as a specialty pharmacy provider for FYARROTM (sirolimus protein-bound particles for injectable suspension) (albumin-bound). FYARRO was ... (Source: McKesson News)
Source: McKesson News - December 22, 2022 Category: Information Technology Source Type: news
